Cochlear relieves Demant of loss-making implant division

Until now, Oticon Medical has been ”strategically important” for Demant, but hasn’t performed on par with expectations. Consequently, the subsidiary will be divested from its parent company, whose CEO says the deal made with the Australian firm is sound.
Photo: Jens Dresling
Photo: Jens Dresling
by christian bundgaard and albert rønning-andersson, translated by daniel pedersen

It is ostensibly not a growing business leg being removed from its parent company.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
  • Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
    Must contain at least 2 characters
    Must contain at least 2 characters

    Get full access for you and your coworkers

    Start a free company trial today

    Share article

    Sign up for our newsletter

    Stay ahead of development by receiving our newsletter on the latest sector knowledge.

    Newsletter terms

    Front page now

    Further reading